Merck’s Molnupiravir—An Independent Newspaper Reports on the Potential Risk for DNA Mutation & Cancer

With heightened excitement centering on the recent announcement by Merck that its  investigational antiviral therapy molnupiravir reduces the risk of hospitalization due to COVID-19, the mainstream press has overwhelmingly served as cheerleader. Developed originally by a group within Emory University called DRIVE, the investigational product was licensed by Ridgeback Biotherapeutics. They attempted to secure taxpayer money during the start of the pandemic from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). Given the government had already awarded the drug’s preliminary developers money, the acting director at the time—and soon- to-be whistleblower Rick Bright expressed concerns about funding this product reported TrialSite. As it turns out the antiviral induces mutations in SARS-CoV-2 purportedly stopping the virus from replicating itself. However preliminary results from a pivotal study showed efficacy and no immediate safety issues so the company halted the study and applied to receive emergency use authorization (EUA). The mainstream press cheered—led by industry’s main man at the top.

Fauci Cheerleads Again
...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee